Hammerhead ribozymes for target validation

Bibliography

• DOHERTY EA, DOUDNA JA: Ribozyme structures and mechanisms. Ann. Rev Biophys. Biomol. Struc. (2001) 30:457–475.
   PubMedGoogle Scholar
• GOODCHILD J: Hammerhead ribozymes: biochemical and chemical considerations. Curr. Opin Mol. Therap. (2000) 2:272–281.
   PubMedGoogle Scholar
• KASHANISABET M, FUNATO T, FLORENES VA, FODSTAD O, SCANLON KJ: Suppression of the neoplastic phenotype in vivo by an anti-ras ribozyme. Cancer Res. (1994) 54:900–902.
   PubMed Web of Science ®Google Scholar
• ••Discriminates between rRNAs that differ atonly a single position within the cleavage site. Suppression of the mutant oncogene had the desired effect on the neoplastic phenotype showing the importance of this protein in transformation.
   Google Scholar
• PHYLACTOU LA, TSIPOURAS E KILPATRICK MW: Hammerhead ribozymes targeted to the FBN1 mRNA can discriminate a single base mismatch between ribozyme and target. Biochem. Biophys. Res. Commun. (1998) 249:804–810.
   PubMed Web of Science ®Google Scholar
• •Discrimination between rRNA targets that differ by only a single nucleotide is possible even when the difference lies outside the cleavage site.
   Google Scholar
• HERSCHLAG D: Implications of ribozyme kinetics for targeting the cleavage of specific RNA molecules in vivo: more isn't always better. Proc. Nati Acad. Sci. USA (1991) 88:6921–6925.
   PubMed Web of Science ®Google Scholar
• HERTEL KJ, HERSCHLAG D, UHLENBECK OC: Specificity of hammerhead ribozyme cleavage. EMBO (1996) 15:3751–3757.
   PubMed Web of Science ®Google Scholar
• ••Determines the tolerance for mismatchesbetween the hammerhead and its substrate and shows that the ability of the hammerhead to discriminate decreases if it forms more than about 12 base pairs with the substrate.
   Google Scholar
• SUN LQ, WANG L, GERLACH WL, SYMONDS G: Target sequence-specific inhibition of HIV-1 replication by ribozymes directed to tat RNA. Nucl. Acids Res. (1995) 23:2909–2913.
   PubMed Web of Science ®Google Scholar
• •The position of a mismatch in the flanking sequences is important and it can prevent cleavage if it is next to the cleavage site.
   Google Scholar
• DEYOUNG MB, KINCADEDENKER J, BOEHM CA et al.: Functional characterization of ribozymes expressed using Ul and T7 vectors for the intracellular cleavage of ANF mRNA. Biochemistry (1994) 33:12127–12138.
   PubMed Web of Science ®Google Scholar
• ••Uses ribonuclease H and antisenseoligonucleotides to compare the accessibility of different GUC sites. This does not correlate with predictions of substrate secondary structure. Two - four mismatches are needed in the stems to prevent cleavage. Ribozymes seem to work better in cells than in vitro.
   Google Scholar
• HOVIG E, MAELANDSMO G, MELLINGSAETER T etal.: Optimization of hammerhead ribozymes for the cleavage of S100A4 (CAPL) mRNA. Anti. Nucl. Add Drug Dis. (2001) 11:67–75.
   Google Scholar
• •The most efficient sites for cleavage must be determined experimentally.
   Google Scholar
• SOHAIL M, SOUTHERN EM: Hybridization of antisense reagents to RNA. Curr. Opin.Mol. Therap. (2000) 2:264–271.
   PubMedGoogle Scholar
• •Describes the unexpected complexities of hybridisation between oligonucleotides and RNA.
   Google Scholar
• MIR AA, LOCKETT TJ, HENDRY P: Identifying ribozyme-accessible sites using NUH triplet-targeting gapmers. Nucl. Adds Res. (2001) 29:1906–1914.
   PubMed Web of Science ®Google Scholar
• ••Describes a method for identifying themost accessible hammerhead cleavage sites within an RNA sequence.
   Google Scholar
• SOHAIL M, HOCHEGGER H, KLOTZBUCHER A, LEGUELLEC R, HUNT T, SOUTHERN EM: Antisense oligonucleotides selected by hybridisation to scanning arrays are effective reagents in vivo. Nucl. Acids Res. (2001) 29:2041–2051.
   PubMed Web of Science ®Google Scholar
• •Optimum oligonucleotide hybridisation sites on an RNA, determined empirically using microarrays, correlate with the most active antisense oligonucleotides in cells. This suggests that secondary structure of RNA is not significantly different inside and outside cells. Also, binding of intracellular proteins to RNA is not a major obstacle to hybridisation.
   Google Scholar
• WEISS B, DAVIDKOVA G, ZHOU LW: Antisense RNA gene therapy for studying and modulating biological processes. Cell. Life Sci. (1999) 55:334–358.
   PubMed Web of Science ®Google Scholar
• LITTLE E, LEE AS: Generation of a mammalian cell line deficient in glucoseregulated protein stress induction through targeted ribozyme driven by a stress-inducible promoter. J. Biol. Chem. (1995) 270:9526–9534.
   PubMed Web of Science ®Google Scholar
• •Transcription of the hammerhead was co-ordinated with its target mRNA by putting both under control of the same stress-inducible promoter.
   Google Scholar
• CAGNON L, ROSSI JJ: Downregulation of the CCRS P-chemokine receptor and inhibition of HIV-1 infection by stable VA1-ribozyme chimeric transcripts. Antisense Nucl. Acid Drug Dis. (2000) 10:251–261.
   PubMedGoogle Scholar
• SULLENGER BA, CECH TR: Tethering ribozymes to a retroviral packaging signal for destruction of viral RNA. Science (1993) 262:1566–1569.
   PubMed Web of Science ®Google Scholar
• ••Demonstrates that the diffusion ofribozymes within a cell may not be adequate for cleavage of a target in a different compartment.
   Google Scholar
• KATO Y, KUWABARA T, WARASHINA M, TODA H, TAIRA K: Relationships between the activities in vitro and in vivo of various kinds of ribozyme and their intracellular localization in mammalian cells. J. Bia. Chem. (2001) 276:15378–15385.
   PubMed Web of Science ®Google Scholar
• •Using different promoters and flanking sequences, hammerheads can be localised within the nucleus or transported into the cytoplasm. Greater activity in the cytoplasm suggests better accessibility of the RNA target.
   Google Scholar
• KUWABARA T, WARASHINA M, KOSEKI S et al.: Significantly higher activity of a cytoplasmic hammerhead ribozyme than a corresponding nuclear counterpart: engineered tRNAs with an extended 3' end can be exported efficiently and specifically to the cytoplasm in mammalian cells. Nucl. Adds Res. (2001) 29:2780–2788.
   PubMed Web of Science ®Google Scholar
• DROPULIC B, JEANG K-T: Intracellular susceptibility to ribozymes in a tethered substrate-ribozyme provirus model is not predicted by secondary structures of human immunodeficiency virus Type 1 RNAs in vitro. Anti. Res. Develop. (1994) 4:217–221.
   PubMedGoogle Scholar
• MICHIENZI A, CAGNON L, BAHNER I, ROSSI JJ: Ribozyme-mediated inhibition of HIV 1 suggests nucleolar trafficking of HIV-1 RNA. Proc. Natl. Acad. Li. USA (2000) 97:8955–8960.
   PubMed Web of Science ®Google Scholar
• SCHERR M, MAURER AB, KLEIN S, GANSER A, ENGELS JW, GREZ M: Effective reversal of a transformed phenotype by retrovirus-mediated transfer of a ribozyme directed against mutant N-ras. Gene Ther. (1998) 5:1227–1234.
   PubMed Web of Science ®Google Scholar
• CHOWRIRA BM, PAVCO PA, MCSWIGGEN JA: In vitro and in vivo comparison of hammerhead, hairpin, and hepatitis delta virus self-processing ribozyme cassettes. j Biol. Chem. (1994) 269:25856–25864.
   PubMed Web of Science ®Google Scholar
• CRONE TM, SCHALLES SL, BENEDICT CM et al: Growth inhibition by a triple ribozyme targeted to repetitive B2 transcripts. Hepatology (1999) 29:1114–1123.
   PubMed Web of Science ®Google Scholar
• CHEN C-J, BANERJEA AC, HARMISON GG, HAGLUND K, SCHUBERT M: Multitarget-ribozyme directed to cleave at up to nine highly conserved HIV-1 env RNA regions inhibits HIV-1 replication-potential effectiveness against most presently sequenced HIV-1 isolates. Nucl. Acids Res. (1992) 20:4581–4589.
   PubMed Web of Science ®Google Scholar
• LEOPOLD LH, SHORE SK, NEWKIRK TA, REDDY RMV, REDDY EP: Multi-unit ribozyme-mediated cleavage of bcr-abl mRNA in myeloid leukemias. Blood (1995) 85:2162–2170.
   PubMed Web of Science ®Google Scholar
• TABLER M, HOMANN M, TZORTZAKAKI S, SCZAKIEL G: A three-nucleotide helix I is sufficient for full activity of a hammerhead ribozyme: advantages of an asymmetric design. Nucl. Acids Res. (1994) 22:3958–3965.
   PubMed Web of Science ®Google Scholar
• MAHIEU M, DESCHUYTENEER R, FORGET D, VANDENBUSSCHE E CONTENT J: Construction of a ribozyme directed against human interleukin-6 mRNA: Evaluation of its catalytic activity in vitro and in vivo. Blood (1994) 84:3758–3765.
   PubMed Web of Science ®Google Scholar
• ENJOJI M, WANG E NAKAMUTA M, CHAN L, TENG BB: Hammerhead ribozyme as a therapeutic agent for hyperlipidemia: production of truncated apolipoprotein B and hypolipidemic effects in a dyslipidemia murine model. Hum. Gene Ther. (2000) 11:2415–2430.
   PubMed Web of Science ®Google Scholar
• ••One of the best demonstrations ofhammerhead cleavage in vivo. The presence of the expected RNA cleavage products and a truncated protein from translation of the clipped mRNA were found.
   Google Scholar
• LANGE W, DASKALAKIS M, FINKE J, DOLKEN G: Comparison of different ribozymes for efficient and specific cleavage of BCR/ABL related mRNAs. FEBS Lett. (1994) 338:175–178.
   PubMed Web of Science ®Google Scholar
• IRIE A, ANDEREGG B, KASHANISABET M et al.: Therapeutic efficacy of an adenovirus-mediated anti-H-ras ribozyme in experimental bladder cancer. Anti. Nucl. Add Drug Dis. (1999) 9:341–349.
   PubMedGoogle Scholar
• ••Injection of anti-H-ras hammerheadadenoviral vectors into mice can give complete regression of some pre-existing tumours.
   Google Scholar
• SIOUD M, NATVIG JB, FORRE O: Preformed ribozyme destroys tumour necrosis factor mRNA in human cells. Biol. (1992) 223:831–835.
   Google Scholar
• VENTURA M, WANG P, FRANCK N, SARAGOSTI S: Ribozyme targeting of HIV-1 LTR. Biochem. Biophys. Res. Commun. (1994) 203:889–898.
   PubMed Web of Science ®Google Scholar
• KIEHNTOPF M, HERRMANN F, BRACH MA: Functional NF-IL6/CCAAT enhancer-binding protein is required for tumor necrosis factor alpha-inducible expression of the granulocyte colony-stimulating factor (CSF), but not the granulocyte/macrophage CSF or interleukin 6 gene in human fibroblasts. j Exp. Med. (1995) 181:793–798.
   PubMed Web of Science ®Google Scholar
• DORAI T, OLSSON CA, KATZ AE, BUTTYAN R: Development of a hammerhead ribozyme against bc1-2.1. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate (1997) 32:246–258.
   Google Scholar
• PRASMICKAITE L, HOGSET A, MAELANDSMO G et al: Intracellular metabolism of a 2'-0-methyl-stabilized ribozyme after uptake by DOTAP transfection or as free ribozyme. A study by capillary electrophoresis. Nucl. Adds Res. (1998) 26:4241–4248.
   PubMed Web of Science ®Google Scholar
• EN GELS JW, SCHERR M, GANSER A,GREZ M, WITTMANN V: Modified hammerhead ribozymes as potential therapeutics. Nucleos. Nucleot. (1998) 17:1685–1696.
   Google Scholar
• KOIZUMI M, KAMIYA H, OHTSUKA E: Ribozymes designed to inhibit transformation of NIH3T3 cells by the activated c-Ha-ras gene. Gene (1992) 117:179–184.
   PubMed Web of Science ®Google Scholar
• FUNATO T, SHITARA T, TONE T, PAO L, KASHANISABET M, SCANLON KJ: Suppression of H-ras-mediated transformation in NIH3T3 cells by a ras ribozyme. Biochem. Pharmacol (1994) 48:1471–1475.
   PubMed Web of Science ®Google Scholar
• OHTA Y, KIJIMA H, KASHANISABET M, SCANLON KJ: Suppression of the malignant phenotype of melanoma cells by anti-oncogene ribozymes. j Invest. Dermatol (1996) 106:275–280.
   PubMed Web of Science ®Google Scholar
• TSUCHIDA T, KIJIMA H, OSHIKA Y et al.: Hammerhead ribozyme specifically inhibits mutant K-ras mRNA of human pancreatic cancer cells. Biochem. Biophys. Res. Commun. (1998) 253:368–373.
   PubMed Web of Science ®Google Scholar
• TOKUNAGA T, TSUCHIDA T, KIJIMA H et al: Ribozyme-mediated inactivation of mutant K-ras oncogene in a colon cancer cell line. Br j Cancer (2000) 83:833–839.
   PubMed Web of Science ®Google Scholar
• SCANLON KJ, RAO L, FUNATO T etal.:Ribozyme-mediated cleavage of c-fos mRNA reduces gene expression of DNA synthesis enzymes and metallothionein. Proc. Natl. Acad. Sci. USA (1991) 88:10591–10595.
   Google Scholar
• YOKOYAMA Y, MORISHITA S, TAKAHASHI Y, HASHIMOTO M, TAMAYA T: Modulation of c-fms proto-oncogene in an ovarian carcinoma cell line by a hammerhead ribozyme. Br I Cancer (1997) 76:977–982.
   PubMed Web of Science ®Google Scholar
• TANG CK, CONCEPCION XZW, MILAN M, GONG XQ, MONTGOMERY E, LIPPMAN ME: Ribozyme-mediated down-regulation of ErbB-4 in estrogen receptor-positive breast cancer cells inhibits proliferation both in vitro and in vivo. Cancer Res. (1999) 59:5315–5322.
   PubMed Web of Science ®Google Scholar
• PARTHASARATHY R, COTE GJ, GAGEL RF: Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res. (1999) 59:3911–3914.
   PubMed Web of Science ®Google Scholar
• CAMERON FH, JENNINGS PA: Specific gene suppression by engineered ribozymes in monkey cells. Proc. Natl. Acad. Li. USA (1989) 86:9139–9143.
   PubMed Web of Science ®Google Scholar
• HA JH, KIM KH: Inhibition of fatty acid synthesis by expression of an acetyl-CoA carboxylase-specific ribozyme gene. Proc. Natl. Acad. Sci. USA (1994) 91:9951–9955.
   PubMed Web of Science ®Google Scholar
• KOBAYASHI H, TAKEMURA Y, MIYACHI H, SKELTON L, JACKMAN AL: Effect of hammerhead ribozyme against human thymidylate synthase on the cytotoxicity of thymidylate synthase inhibitors. him J. Cancer Res. (1995) 86:1014–1018.
   Web of Science ®Google Scholar
• HUA J, MUSCHEL RJ: Inhibition of matrix metalloproteinase 9 expression by a ribozyme blocks metastasis in a rat sarcoma model system. Cancer Res. (1996) 56:5279–5284.
   PubMed Web of Science ®Google Scholar
• KIJIMA H, TSUCHIDA T, KONDO H et al.: Hammerhead ribozymes against gamma-glutamylcysteine synthetase mRNA down-regulate intracellular glutathione concentration of mouse islet cells. Biochem. Biophys. Res. Commun. (1998) 247:697–703.
   PubMed Web of Science ®Google Scholar
• PATRICIA MK, NATARAJAN R, DOOLEY AN et al.: Adenoviral delivery of a leukocyte-type 12 lipoxygenase ribozyme inhibits effects of glucose and platelet-derived growth factor in vascular endothelial and smooth muscle cells. Circ. Res. (2001) 88:659–665.
   PubMed Web of Science ®Google Scholar
• XU RH, LIU J, CHEN XW et al.: Ribozyme-mediated inhibition of caspase-3 activity reduces apoptosis induced by 6-hydroxydopamine in PC12 cells. Brain Res. (2001) 899:10–19.
   PubMed Web of Science ®Google Scholar
• DORAI T, KOBAYASHI H, HOLLAND JF, OHNUMA T: Modulation of platelet-derived growth factor-beta mRNA expression and cell growth in a human mesothelioma cell line by a hammerhead ribozyme. Mel Pharinacol (1994) 46:437–444.
   PubMed Web of Science ®Google Scholar
• LIEBER A, STRAUSS M: Selection of efficient cleavage sites in target RNAs by using a ribozyme expression library. Mel Cell. Biol. (1995) 15:540–551.
   Web of Science ®Google Scholar
• CZUBAYKO F, DOWNING SG, HSIEH SS et al.: Adenovirus-mediated transduction of ribozymes abrogates HER-2/neu and pleiotrophin expression and inhibits tumor cell proliferation. Gene Ther. (1997) 4:943–949.
   PubMed Web of Science ®Google Scholar
• LUI VWY, HE YK, GOYAL K, HUANG L: Specific down-regulation of HER-2/neu mediated by a chimeric U6 hammerhead ribozyme results in growth inhibition of human ovarian carcinoma. Mol. Ther. (2001) 3:169–177.
   PubMed Web of Science ®Google Scholar
• YAMAZAKI H, KIJIMA H, OHNISHI Y et al.: Inhibition of tumor growth by ribozyme-mediated suppression of aberrant epidermal growth factor receptor gene expression. j Natl. Cancer Inst. (1998) 90:581–587.
   PubMed Web of Science ®Google Scholar
• TSUJI H, IEHARA N, MASEGI T et al.:Ribozyme targeting of receptor for advanced glycation end products in mouse mesangial cells. Biochem. Biophys. Res. Commun. (1998) 245:583–588.
   PubMed Web of Science ®Google Scholar
• KAWASAKI H, ECKNER R, YAO TP et al.: Distinct roles of the co-activators p300 and CBP in retinoic-acid-induced F9-cell differentiation. Nature (1998) 393:284–289.
   PubMed Web of Science ®Google Scholar
• XU ZD, OEY L, MOHAN S etal.: Hammerhead ribozyme-mediated cleavage of the human insulin-like growth factor-II ribonucleic acid in vitro and in prostate cancer cells. Endocrinology (1999) 140:2134–2144.
   Google Scholar
• LAVROVSKY Y, TYAGI RK, CHEN S, SONG CS, CHATTERJEE B, ROY AK: Ribozyme-mediated cleavage of the estrogen receptor messenger RNA and inhibition of receptor function in target cells. Mel Endocrine]. (1999) 13:925–934.
   PubMedGoogle Scholar
• WANG Q, MULLAH BK, ROBISHAW JD: Ribozyme approach identifies a functional association between the G protein beta(1)gamma(7) subunits in the beta-adrenergic receptor signaling pathway. J Biof Chem. (1999) 274:17365–17371.
   PubMed Web of Science ®Google Scholar
• ABOUNADER R, RANGANATHAN S, LAL B et al.: Reversion of human glioblastoma malignancy by Ul small nuclear RNA/ribozyme targeting of scatter factor/hepatocyte growth factor and c-met expression. J. Natl. Cancer Inst. (1999) 91:1548–1556.
   PubMed Web of Science ®Google Scholar
• SU JZ, FUKUDA N, HU WY, KANMATSUSE K: Ribozyme to human TGF-beta 1 mRNA inhibits the proliferation of human vascular smooth muscle cells. Biochem. Biophys. Res. Commun. (2000) 278:401–407.
   PubMed Web of Science ®Google Scholar
• OSHIKA Y, NAKAMURA M, TOKUNAGA T et al.: Ribozyme approach to downregulate vascular endothelial growth factor (VEG9 189 expression in non-small cell lung cancer (NSCLC). Eur. J. Cancer (2000) 36:2390–2396.
   PubMed Web of Science ®Google Scholar
• BAI JR, GORANTLA S, BANDA N, CAGNON L, ROSSI J, AKKINA R: Characterization of anti-CCR5 ribozyme-transduced CD34(+) hematopoietic progenitor cells in vitro and in a SCID-hu mouse model in vivo. Mol. Ther. (2000) 1:244–254.
   PubMed Web of Science ®Google Scholar
• ZHAO JJ, LEMKE G: Selective disruption of neuregulin-1 function in vertebrate embryos using ribozyme-tRNA transgenes. Development (1998) 125: 1899-1907.
   Google Scholar
• •Inhibition of neuregulirt-1 in chick embryos was studied using a hammerhead, as gene knockout of this protein is lethal.
   Google Scholar
• NYLANDSTED J, ROHDE M, BARTEK J, STRAUSS M: Expression of a p16(INK4a)-specific ribozyme downmodulates p16(INK4a) abundance and accelerates cell proliferation. FEBS Lett. (1998) 436:41–45.
   PubMed Web of Science ®Google Scholar
• PERLMAN H, SATA M, KRASINSKI K, DORAI T, BUTTYAN R, WALSH K: Adenovirus-encoded hammerhead ribozyme to Bc1-2 inhibits neointimal hyperplasia and induces vascular smooth muscle cell apoptosis. Cardiovasc. Res. (2000) 45:570–578.
   PubMed Web of Science ®Google Scholar
• WRIGHT LA, MILLIKEN S, BIGGS JC, KEARNEY P: Ex vivo effects associated with the expression of a bcr-abl-specific ribozyme in a CML cell line. Anti. Nucl. Acids Drug Dis. (1998) 8:15–23.
   PubMedGoogle Scholar
• KUWABARA T, WARASHINA M, TANABE T, TANI K, ASANO S, TAIRA K: A novel allosterically trans-activated ribozyme, the maxizyme, with exceptional specificity in vitro and in vivo. Mol. Cell. (1998) 2:617–627.
   PubMed Web of Science ®Google Scholar
• EHUILLIER PJ, DAVIS SR, BELLAMY AR: Cytoplasmic delivery of ribozymes leads to efficient reduction in alpha-lactalbumin messenger RNA levels in C1271 mouse cells. EMBO J. (1992) 11:4411–4418.
   PubMed Web of Science ®Google Scholar
• DENMAN RB, SMEDMAN M, JU WN, RUBENSTEIN R, POTEMPSKA A, MILLER DL: Ribozyme mediated degradation of beta-amyloid peptide precursor mrRNA in COS-7 cells. Nucl. Acids Res. (1994) 22:2375–2382.
   PubMed Web of Science ®Google Scholar
• DUAN LX, POMERANTZ RJ: Elimination of endogenous aberrant kappa chain transcripts from sp2/0-derived hybridoma cells by specific ribozyme cleavage: utility in genetic therapy of HIV-1 infections. Nucl. Acids Res. (1994) 22:5433–5438.
   PubMed Web of Science ®Google Scholar
• FENG B, ROLLO EE, DENHARDT DT: Osteopontin (OPN) may facilitate metastasis by protecting cells from macrophage NO-mediated cytotoxicity: Evidence from cell lines down-regulated for OPN expression by a targeted ribozyme. OM. Exp. Metastasis (1995) 13:453–462.
   PubMed Web of Science ®Google Scholar
• MAELANDSMO GM, HOVIG E, SKREDE M etal.: Reversal of the in vivo metastatic phenotype of human tumor cells by an anti-CAPL (mts 1) ribozyme. Cancer Res. (1996) 56:5490–5498.
   Google Scholar
• MATSUSHITA H, KOBAYASHI H, MORI S, KIZAKI M, IKEDA Y: Ribozymes cleave the AML1/MTG8 fusion transcript and inhibit proliferation of leukemic cells with t(8;21). Biochem. Biophys. Res. Commun. (1995) 215:431–437.
   PubMed Web of Science ®Google Scholar
• HOLM PS, SCANLON KJ, DIETEL M: Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br I Cancer (1994) 70:239–243.
   PubMed Web of Science ®Google Scholar
• CIARDIELLO F, TORTORA G, BIANCO C et al.: Inhibition of cripto expression and tumorigenicity in human colon cancer cells by antisense RNA and oligodeoxynucleotides. Oncogerre (1994) 9:291–298.
   PubMed Web of Science ®Google Scholar
• YOKOYAMA Y, TAKAHASHI Y, SHINOHARA A etal.: Attenuation of telomerase activity by a hammerhead ribozyme targeting the template region of telomerase RNA in endometrial carcinoma cells. Cancer Res. (1998) 58:5406–5410.
   Google Scholar
• JARVIS TC, ALBY LJ, BEAUDRY AA et al.: Inhibition of vascular smooth muscle cell proliferation by ribozymes that cleave c-myb mRNA. RIVA (1996) 2:419–428.
   Google Scholar
• GIANNINI CD, ROTH WK, PIIPER A, ZEUZEM S: Enzymatic and antisense effects of a specific anti-Ki-ras ribozyme in vitro and in cell culture. Nucl. Acid. Res. (1999) 27:2737–2744.
   PubMed Web of Science ®Google Scholar
• GU J-L, VEERAPANANE D, ROSSI J, NATARAJAN R, THOMAS L, NADLER J: Ribozyme-mediated inhibition of expression of leukocyte-type 12-lipoxygnease in porcine aortic vascular smooth muscle cells. Circ. Res. (1995) 77:14–20.
   PubMed Web of Science ®Google Scholar
• SIOUD M: Ribozyme modulation of lipopolysaccharide-induced tumor necrosis factor-a production by peritoneal cells in vitro and in vivo. Eur. Immurrol. (1996) 26:1026–1031.
   PubMed Web of Science ®Google Scholar
• WANG Q, MULLAH B, HANSEN C, ASUNDI J, ROBISHAW JD: Ribozyme-mediated suppression of the G protein gamma(7) subunit suggests a role in hormone regulation of adenylylcyclase activity. I Biol. Chem. (1997) 272:26040–26048.
   Web of Science ®Google Scholar
• DORAI T, GOLUBOFF ET, OLSSON CA, BUTTYAN R: Development of a hammerhead ribozyme against BCL-2.2. Ribozyme treatment sensitizes hormone-resistant prostate cancer cells to apoptotic agents. Anticancer Res. (1997) 17:3307–3312.
   Google Scholar
• HU WY, FUKUDA N, NAKAYAMA M, KISHIOKA H, KANMATSUSE K: Inhibition of vascular smooth muscle cell proliferation by DNA-RNA chimeric hammerhead ribozyme targeting to rat platelet-derived growth factor A-chain mRNA. I Hypertension (2001) 19:203–212.
   PubMed Web of Science ®Google Scholar
• SNYDER DS, WU YP WANG JL et al.: Ribozyme-mediated inhibition of bcr-abl gene expression in a Philadelphia chromosome-Positive cell line. Blood (1993) 82:600–605.
   Google Scholar
• SHORE SK, NABISSA PM, REDDY EP:Ribozyme-mediated cleavage of the BCRABL oncogene transcript; in vitro cleavage of RNA and in vivo loss of P210 protein-kinase activity. Oricogerie (1993) 8:3183–3188.
   Google Scholar
• BERTRAM J, PALFNER K, KILLIAN Met al.: Reversal of multiple drug resistance in vitro by phosphorothioate oligonucleotides and ribozymes. Anticancer Drugs (1995) 6:124–134.
   Google Scholar
• ZHANG YA, NEMUNAITIS J, SCANLON KJ, TONG AW: Anti-tumorigenic effect of a K-ras ribozyme against human lung cancer cell line heterotransplants in nude mice. Gene Therapy (2000) 7:2041–2050.
   PubMed Web of Science ®Google Scholar
• ••Injection of anti-K-ras hammerheadadenoviral vectors into mice can give complete regression of some pre-existing tumours.
   Google Scholar
• EFRAT S, LEISER M, WU YJ etal.: Ribozyme-mediated attenuation of pancreatic 13-cell glucokinase expression in transgenic mice results in impaired glucose-induced insulin secretion. Proc. Natl. Acad. Sci. USA (1994) 91:2051–2055.
   Google Scholar
• PARRY TJ, CUSHMAN C, GALLEGOS AM et al.: Bioactivity of anti-angiogenic ribozymes targeting Flt-1 and KDR mRNA. Nucl. Acid Res. (1999) 27:2569–2577.
   PubMed Web of Science ®Google Scholar
• LIEBER A, KAY MA: Adenovirus-mediatedexpression of ribozymes in mice. I Viral. (1996) 70:3153–3158.
   Google Scholar
• LARSSON S, HOTCHKISS G, ANDANG M et al.: Reduced beta 2-microglobulin mRNA levels in transgenic mice expressing a designed hammerhead ribozyme. Nucl. Acids Res. (1994) 22:2242–2248.
   PubMed Web of Science ®Google Scholar
• ZHAO JJ, PICK L: Generating loss-of-function phenotypes of the fushi tarazy gene with a targeted ribozyme in Drosophila. Nature (1993) 365:448–451.
   PubMed Web of Science ®Google Scholar
• •A heat shock inducible promoter was used to switch on hammerhead expression at a specific stage of development in transgenic fruit fly embryos.
   Google Scholar
• LHUILLIER PJ, SOULIER S, STINNAKRE MG etal.: Efficient and specific ribozyme-mediated reduction of bovine ot-lactalbumin expression in double transgenic mice. Proc. Natl. Acad. Sci. USA (1996) 93:6698–6703.
   Google Scholar
• LAVAIL MM, YASUMURA D, MATTHES MT etal.: Ribozyme rescue of photoreceptor cells in P23H transgenic rats: Long-term survival and late-stage therapy. Proc. Nat. Acad. Li. USA (2000) 97:11488–11493.
   Google Scholar
• ALAMI R, GILMAN JG, FENG YQ et al.:Anti beta(S)-ribozyme reduces beta(S) mRNA levels in transgenic mice: Potential application to the gene therapy of sickle cell anemia. Blood Cells Ma. Dis. (1999) 25:110–118.
   PubMed Web of Science ®Google Scholar
• HEINRICH JC, TABLER M, LOUIS C: Attenuation of white gene expression in transgenic drosophila-melanogaster - possible role of a catalytic antisense RNA. Dev. Genet. (1993) 14:258–265.
   PubMedGoogle Scholar
• SIOUD M, SORENSEN DR: A nuclease-resistant protein kinase C alpha ribozyme blocks glioma cell growth. Nat. Biotechnol. (1998) 16:556–561.
   PubMed Web of Science ®Google Scholar
• ••Modification of the ribozyme increases itshalf-life 14,000 times in serum. Injection of liposome-bound hammerhead into tumours suppresses growth and sheds light on the function of PKC-a.
   Google Scholar
• DESJARDINS JP, SPROAT BS, BEIJER B et al.: Pharmacokinetics of a synthetic, chemically modified hammerhead ribozyme against the rat cytochrome P-450 3A2 mRNA after single intravenous injections. Pharmacol. Esp. Ther. (1996) 278:1419–1427.
   PubMed Web of Science ®Google Scholar
• GU JL, PEI H, THOMAS L etal.: Ribozyme-mediated inhibition of rat leukocyte-type 12-lipoxygenase prevents intimal hyperplasia in balloon-injured rat carotid arteries. Circulation (2001) 103:1446–1452.
   Google Scholar
• ••In vivo validation of a target for restenosisusing a synthetic hammerhead. The crippled control ribozyme with a single change in the catalytic core was inactive.
   Google Scholar
• FLORY CM, PAVCO PA, JARVIC TC etal.: Nuclease-resistant ribozymes decrease stromelysin mRNA levels in rabbit synovium following exogenous delivery to the knee joint. Proc. Nati Acad. Li. USA (1996) 93:754–758.
   Google Scholar
• •Modified hammerheads survive up to 7 days in the synovium and are taken up into cells. This targets a protease involved in tissue damage caused by arthritis.
   Google Scholar
• YAMAMOTO K, MORISHITA R, TOMITA N et al.: Ribozyme oligonucleotides against transforming growth factor-3 inhibited neointimal formation after vascular injury in rat model - potential application of ribozyme strategy to treat cardiovascular disease. Circulation (2000) 102:1308–1314.
   PubMed Web of Science ®Google Scholar
• •In vivo validation of a target for restenosis using a synthetic hammerhead.
   Google Scholar
• SANDBERG JA, BOUHANA KS, GALLEGOS AM et al.: Pharmacokinetics of an antiangiogenic ribozyme (Angiozyme") in the mouse. Anti. Nucl. Add Drug Dis. (1999) 9:271–277.
   PubMedGoogle Scholar
• SALMI P, SPROAT BS, LUDWIG J et Dopamine D-2 receptor ribozyme inhibits quinpirole-induced stereotypy in rats. Eur. Pharmacol. (2000) 388:R1–R2.
   Web of Science ®Google Scholar
• LYNGSTADAAS SE RISNES S, SPROAT BS, THRANE PS, PRYDZ HP: A synthetic, chemically modified ribozyme eliminates amelogenin, the major translation product in developing mouse enamel in vivo. EMBO J. (1995) 14:5224–5229.
   PubMed Web of Science ®Google Scholar
• ZAMORE PD: RNA interference: listening to the sound of silence. Nat. Struct. Biol. (2001) 8:746–750.
   PubMedGoogle Scholar
• GIOVANNANGELI C, HELENE C: Triplex-forming molecules for modulation of DNA information processing. Curr. Opin. Mol. Ther. (2000) 2:288–296.
   PubMed Web of Science ®Google Scholar
• STOCKWELL BR: Frontiers in chemical genetics. Trends Biotech. (2000) 18:449–455.
   PubMed Web of Science ®Google Scholar
• LEBEDEVA I, STEIN CA: Antisense oligonucleotides: promise and reality. Ann. Rev Pharmacol. Taxied. (2001) 41:403–419.
   PubMed Web of Science ®Google Scholar
• STEIN CA: The experimental use of antisense oligonucleotides: a guide for the perplexed. J. Clin. Invest. (2001) 108:641–644.
   PubMed Web of Science ®Google Scholar
• KOZIOLKIEWICZ M, GENDASZEWSKA E, MASZEWSKA M, STEIN CA, STEC WJ: The mononucleotide-dependent, nonantisense mechanism of action of phosphodiester and phosphorothioate oligonucleotides depends upon the activity of an ecto-5'-nucleotidase. Blood (2001) 98:995–1002.
   PubMed Web of Science ®Google Scholar
• KRIEG AM: From bugs to drugs: therapeutic immunomodulation with oligodeoxynucleotides containing CpG sequences from bacterial DNA. Antisense. Nucl. Add Drug Dis. (2001) 11:181–188.
   PubMedGoogle Scholar
• LESNIK EA, FREIER SM: What affects the effect of 2'-alkoxy modifications? 1. Stabilization effect of 2'-methoxy substitutions in uniformly modified DNA oligonucleotides. Biochemistry (1998) 37:6991–6997.
   Google Scholar
• FARIA M, SPILLER DG, DUBERTRET C et al.: Phosphoramidate oligonucleotides as potent antisense molecules in cells and in vivo. Nat. Biotechnol. (2001) 19:40–44.
   PubMed Web of Science ®Google Scholar
• NIELSEN PE: Antisense peptide nucleic acids. Curr. Opin Md. Ther. (2000) 2:282–287.
   PubMedGoogle Scholar
• IVERSEN PL: Phosphorodiamidate morpholino oligomers: favorable properties for sequence-specific gene inactivation. Curr. Opin. Mol. Ther. (2001) 3:235–238.
   PubMedGoogle Scholar
• BENNETT FC, COWSERT LM: Application of antisense oligonucleotides for gene functionalization and target validation. Curr. Opin. Mol. Ther. (1999) 1:359–371.
   PubMed Web of Science ®Google Scholar
• KUWABARA T, WARASHINA M, TAIRA K: Allosterically controllable maxizymes cleave mRNA with high efficiency and specificity. Trends Biotech. (2000) 18:462–468.
   PubMed Web of Science ®Google Scholar
• LI YF, BREAKER RR: Deoxyribozymes: new players in the ancient game of biocatalysis. Cun: Opin Struct. Biol. (1999) 9:315–323.
   PubMed Web of Science ®Google Scholar